How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

128,667 results for

Demulen 1/35

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

181. Assessment of antenatal ultrasound after 35 weeks gestation in diagnosing large-for-gestational age fetuses: a systematic review and meta-analysis

Assessment of antenatal ultrasound after 35 weeks gestation in diagnosing large-for-gestational age fetuses: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith (...) based on title and abstract, followed by full-text screening of the eligible articles for final inclusion. In each phase, 2 observers will independently assess each article. Discrepancies will be resolved through discussion, or by consulting a third investigator. ">Procedure for study selection Example : Title-abstract screening: 1. Not an original full research paper (e.g. review, editorial) 2. Not an in vivo animal study 3. No metastases/ only primary tumor 4. No control group 5. Combination

2018 PROSPERO

182. Age-related natural fertility outcomes in women over 35: an individual patient data meta-analysis

Age-related natural fertility outcomes in women over 35: an individual patient data meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address (...) screening of the eligible articles for final inclusion. In each phase, 2 observers will independently assess each article. Discrepancies will be resolved through discussion, or by consulting a third investigator. ">Procedure for study selection Example : Title-abstract screening: 1. Not an original full research paper (e.g. review, editorial) 2. Not an in vivo animal study 3. No metastases/ only primary tumor 4. No control group 5. Combination therapy or contamination 6. Not about analgesics used

2018 PROSPERO

183. The effects of exercise on executive function amongst younger adults (18-35 years): a systematic review of intervention studies

The effects of exercise on executive function amongst younger adults (18-35 years): a systematic review of intervention studies Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne (...) and abstract, followed by full-text screening of the eligible articles for final inclusion. In each phase, 2 observers will independently assess each article. Discrepancies will be resolved through discussion, or by consulting a third investigator. ">Procedure for study selection Example : Title-abstract screening: 1. Not an original full research paper (e.g. review, editorial) 2. Not an in vivo animal study 3. No metastases/ only primary tumor 4. No control group 5. Combination therapy or contamination 6

2018 PROSPERO

184. Inotersen (Tegsedi) - for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis (hATTR)

Inotersen (Tegsedi) - for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis (hATTR) Published 12 August 2019 1 SMC2188 inotersen 284mg solution for injection in pre-filled syringe (Tegsedi®) Akcea Therapeutics UK Ltd 5 July 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice (...) is summarised as follows: ADVICE: following a full submission considered under the ultra-orphan process inotersen (Tegsedi ® ) is accepted for use within NHSScotland. Indication under review: for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis (hATTR). In a phase II/III study of adults with hATTR and polyneuropathy, inotersen was associated with significantly less worsening compared with placebo, measured by the change in modified neuropathy

2019 Scottish Medicines Consortium

185. MKSAP: 35-year-old woman is evaluated for intermittent fever

MKSAP: 35-year-old woman is evaluated for intermittent fever Patients at high risk for posttransplant lymphoproliferative disease MKSAP: 35-year-old woman is evaluated for intermittent fever | | May 12, 2018 6 Shares Test your medicine knowledge with the , in partnership with the . A 35-year-old woman is evaluated for intermittent fever, sweats, fatigue, and dull midchest pain of 2 weeks’ duration. Medical history is significant for liver transplantation 6 months ago for primary biliary (...) is at increased risk for PTLD because she was seronegative for Epstein-Barr virus (EBV) and the organ donor was seropositive. PTLD is related to B-cell proliferation induced by infection with EBV in the setting of chronic immunosuppression and resulting decreased T-cell immune surveillance. She presents within a typical timeframe (first few months to 1 year after transplantation) with lymphadenopathy found on CT scan and systemic symptoms consistent with PTLD. In addition to PTLD, EBV after transplantation

2018 KevinMD blog

186. Elite football teams that do not have a winter break lose on average 303 player-days more per season to injuries than those teams that do: a comparison among 35 professional European teams. Full Text available with Trip Pro

Elite football teams that do not have a winter break lose on average 303 player-days more per season to injuries than those teams that do: a comparison among 35 professional European teams. To compare injury rates among professional men's football teams that have a winter break in their league season schedule with corresponding rates in teams that do not.56 football teams from 15 European countries were prospectively followed for seven seasons (2010/2011-2016/2017)-a total of 155 team-seasons (...) . Individual training, match exposure and time-loss injuries were registered. Four different injury rates were analysed over four periods within the season, and linear regression was performed on team-level data to analyse the effect of winter break on each of the injury rates. Crude analyses and analyses adjusted for climatic region were performed.9660 injuries were reported during 1 447 011 exposure hours. English teams had no winter break scheduled in the season calendar: the other European teams had

2018 British Journal of Sports Medicine

187. Adult Type 1 diabetes mellitus

Awareness and management of hypoglycaemia 31 3.11 Ketone monitoring and management of diabetic ketoacidosis (DKA) 32 3.12 Associated illness 34 3.13 Control of cardiovascular risk 34 3.14 Care of adults with type 1 diabetes in hospital 35 3.15 Pre-pregnancy care 36 3.16 Managing complications 378 | Adult type 1 diabetes mellitus | A National Clinical Guideline Section 4: Appendices 42 Appendix 1: Terms of reference for the Guideline Development Group 42 Appendix 2: Recommendations from NICE NG17 (...) Adult Type 1 diabetes mellitus Adult type 1 diabetes mellitus National Clinical Guideline No. 17 National Patient Safety Office Oifig Náisiúnta um Shábháilteacht Othar June 2018This National Clinical Guideline for adults with type 1 diabetes has been developed by the Guideline Development Group, supported by the HSE National Clinical Programme for Diabetes. Part of the process of developing this guideline involved contextualising (for Ireland) the National Institute for Health and Care

2018 National Clinical Guidelines (Ireland)

188. Care of Adults with Neurofibromatosis Type 1

Care of Adults with Neurofibromatosis Type 1 Care of adults with neurofibromatosis type 1: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG) Douglas R. Stewart, MD 1 , Bruce R. Korf, MD, Ph.D 2 , Katherine L. Nathanson, MD 3,4 , David A. Stevenson, MD 5 and Kaleb Yohay, MD 6 Purpose: Neurofibromatosis type 1 (NF1) is an autosomal dominant disorder that is caused by a heterozygous loss-of- function variant in the tumor suppressor gene NF1; it affects ~1 (...) /1,900–1/3,500 people worldwide. The disorder is associated with an 8–15-year reduction in average life expectancy in both men and women, primarily due to malignant neoplasms and cardio- vascular causes. Methods: A work group of experts sought to determine the prevalence, morbidity and mortality, and available treatments of common and emerging NF1-related clinical problems in adults. Work-group members identified peer-reviewed publications from PubMed. Publications derived from populations and multi

2018 American College of Medical Genetics and Genomics

189. HiQuiPs: Preparation Part 1 – General Considerations for ED Quality Improvement Projects Full Text available with Trip Pro

HiQuiPs: Preparation Part 1 – General Considerations for ED Quality Improvement Projects HiQuiPs: Preparation Part 1 - General Considerations for ED Quality Improvement Projects - CanadiEM HiQuiPs: Preparation Part 1 – General Considerations for ED Quality Improvement Projects In , by Ahmed Taher August 29, 2018 You are in the middle of a busy night shift and you see a 73-year-old female with diffuse abdominal pain who is hemodynamically stable. You have a wide differential and order a CT scan (...) frameworks for thinking about QI in the ED, including key QI terminology, the Donabedian model of quality measures, data collection, and examples of consensus-based quality measures. 1 As you start to think of your potential QI project, you wonder if you have identified an appropriate QI initiative. While there are a plethora of QI issues to tackle, the following questions may help guide which practical areas to target: 2 Is the initiative important with implications for patient care? Does the initiative

2018 CandiEM

190. Bictegravir-emtricitabine-tenofovir alafenamide (Biktarvy) - For the treatment of adults infected with HIV-1 without any known mutations associated with resistance to the individual components.

Bictegravir-emtricitabine-tenofovir alafenamide (Biktarvy) - For the treatment of adults infected with HIV-1 without any known mutations associated with resistance to the individual components. Published 10 September 2018 1 bictegravir 50mg / emtricitabine 200mg / tenofovir alafenamide 25mg film- coated tablet (Biktarvy ® ) SMC2093 Gilead Sciences Ltd 10 August 2018 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug (...) and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows: ADVICE: following a full submission bictegravir / emtricitabine / tenofovir alafenamide (Biktarvy ® ) is accepted for use within NHSScotland. Indication under review: Treatment of adults infected with human immunodeficiency virus 1 (HIV-1) without present or past evidence of viral resistance to the integrase inhibitor class, emtricitabine or tenofovir. Bictegravir / emtricitabine / tenofovir alafenamide was non

2018 Scottish Medicines Consortium

191. Newer Drugs for Type 2 Diabetes: An Emerging Adjunctive Therapy to Insulin for Type 1 Diabetes?

See Table 2 for description See Table 2 for description Sitagliptin Garg et al. 2013 22 N = 125 Design Randomized, double-blind, placebo-controlled study (study phase not reported) Patent Population Patients aged 18 to 70 years who had had T1D for > 1 year, had been treated with either multiple daily insulin injections or CSII, had been on a stable insulin dose for ≥ 1 month, routinely tested blood glucose at least 2 to 4 times daily, and had an A1C level of between 7.5% and 10%, and a BMI of < 35 (...) with a stable regimen of multiple daily insulin injections or CSII for ≥ 8 weeks, and had an A1C level of 7.0 to 9.0% and a BMI of 21 to 35 kg/m 2 Interventions Canagliflozin 100 mg P.O. daily Canagliflozin 300 mg P.O. daily Comparison Placebo Duration 18 weeks Proportion of patients with A1C reduction ≥ 0.4% and no increase in body weight at 18 weeks (1 o outcome), % Canagliflozin 100 mg: 36.9 a Canagliflozin 300 mg: 41.4 a Placebo: 14.5 a < 0.001 for both comparisons vs. placebo Change in A1C from

2018 CADTH - Issues in Emerging Health Technologies

192. HiQuiPs: Implementation Part 1 – QI Implementation Methodologies Full Text available with Trip Pro

HiQuiPs: Implementation Part 1 – QI Implementation Methodologies HiQuiPs: Implementation Part 1 - QI Implementation Methodologies - CanadiEM HiQuiPs: Implementation Part 1 – QI Implementation Methodologies In , by Ahmed Taher December 7, 2018 In this two-part series, we will take a deeper dive into several QI conceptual frameworks, or ways to approach QI projects. In our previous posts, we discussed preparation strategies for QI projects; but when it comes to implementing a change, how would (...) can be categorized along a continuum of effective. The basic tenet of this hierarchy is that the more an intervention is reliant on individuals repeatedly performing a specific task in a consistent way, the less likely it is to achieve a consistent and sustainable change. In other words, it is only by changing the system itself that one can ensure reliable and effective improvements. This hierarchy of effectiveness is illustrated below. 1 Keeping the different types of interventions in mind

2018 CandiEM

193. Pain control in surgical abortion part 1 ? local anesthesia and minimal sedation

Pain control in surgical abortion part 1 ? local anesthesia and minimal sedation Reviewarticle SocietyofFamilyPlanningclinicalguidelinespaincontrolinsurgical abortionpart1 —localanesthesiaandminimalsedation RebeccaH.Allen a, ?,RameetSingh b a ObstetricsandGynecology,WarrenAlpertMedicalSchoolofBrownUniversity,WomenandInfantsHospital,101DudleyStreet,Providence,RI02905 b DivisionofFamilyPlanning,DepartmentofObstetricsandGynecology,UniversityofNewMexicoSchoolofMedicine,Albuquerque,NM87131 abstract (...) Nonsteroidalanti-in?ammatorydrugs Contents Background 471 Clinicalquestions 472 Conclusionsandrecommendations 475 Recommendationsforfutureresearch 476 Sources 476 Authorship 476 Con?ictofinterest 476 Intendedaudience 476 References 476 Background Pain experienced during an abortion procedure is in?uenced by a complexinterplayofphysical,psychological,socialandmedicalfactors [1].Painrelatedtosurgicalabortionstemsfromstimulationofthesensory ?bersthatinnervatetheuterusandcervix.Impulsestransmittedvianeu

2018 Society of Family Planning

194. Diagnostic testing for ROS proto-oncogene 1 (ROS1) rearrangements in non-small cell lung cancer (NSCLC) to determine eligibility for crizotinib treatment

/46 (9%) 100% 100% Reguart 2017 108 nCounter Prep Station™ and Digital Analyzer™ ZytoLight SPEC ROS1 probe 27/79 (35%) 70% 96% FISH = fluorescent in-situ hybridisation; IHC = immunohistochemistry; NGS = next-generation sequencing; NPV = negative predictive value; pos = positive; PCR = polymerase chain reaction; PPV = positive predictive value; RNA = ribonucleic acid; RO S1 = RO S proto- oncogene 1; RT-PCR = reverse transcription polymerase chain reaction. a May be higher than the denominator (...) Diagnostic testing for ROS proto-oncogene 1 (ROS1) rearrangements in non-small cell lung cancer (NSCLC) to determine eligibility for crizotinib treatment 1 Public Summary Document Application No. 1454- Diagnostic testing for ROS proto-oncogene1 (ROS1) rearrangements in patients with non-small cell lung cancer (NSCLC) to determine eligibility for crizotinib treatment Applicant: Pfizer Australia Pty Ltd Date of MSAC consideration: MSAC 71 st Meeting, 23 November 2017 Context for decision: MSAC

2017 Medical Services Advisory Committee

195. National Clinical Guideline on Adult type 1 diabetes mellitus

Insulin delivery 30 3.9 Referral for islet or pancreas transplantation 31 3.10 Awareness and management of hypoglycaemia 31 3.11 Ketone monitoring and management of diabetic ketoacidosis (DKA) 32 3.12 Associated illness 34 3.13 Control of cardiovascular risk 34 3.14 Care of adults with type 1 diabetes in hospital 35 3.15 Pre-pregnancy care 36 3.16 Managing complications 378 | Adult type 1 diabetes mellitus | A National Clinical Guideline Section 4: Appendices 42 Appendix 1: Terms of reference (...) National Clinical Guideline on Adult type 1 diabetes mellitus Adult type 1 diabetes mellitus National Clinical Guideline No. 17 National Patient Safety Office Oifig Náisiúnta um Shábháilteacht Othar June 2018This National Clinical Guideline for adults with type 1 diabetes has been developed by the Guideline Development Group, supported by the HSE National Clinical Programme for Diabetes. Part of the process of developing this guideline involved contextualising (for Ireland) the National

2018 HIQA Guidelines

196. GLP-1 Agonists (liraglutide)

GLP-1 Agonists (liraglutide) MED CHECK - TIP December 2016 / Vol.2 No.6 · Page 27 -The Informed Prescriber C N o 6 M ED HECK Volume 2 December 2 0 1 6 Nivolumab (brand name: Opdivo) Editorial: Don’t be misled by new “mab” drugs New Products New anticancer drug Nivolumab (brand name: Opdivo) GLP-1 Agonists (liraglutide etc.) CONTENTS (December 2016, Vol. 2, No. 6) 28 29 35 Benefit and harm on survival offset each other: strict restriction on use is needed GLP-1 Agonists (liraglutide) No evidence (...) 3 months. However, when a PD-L1 expression level is low, nivolumab might shorten life under some conditions. The drug is worthless as it possibly shortens life while the annual drug cost amounts to as high as 35 million yen. Conditions in which the drug is ineffective or harm outweighs, such as “aged 75 or older”, “EGFR mutation”, “K-RAS mutation”, “non-smoking” and “types of prior medications”, should be determined. Under such conditions, the drug should not be used. 1) Center for Cancer

2017 Med Check - The Informed Prescriber

197. Tuberculous meningitis is associated with higher cerebrospinal HIV-1 viral loads compared to other HIV-1-associated meningitides. Full Text available with Trip Pro

Tuberculous meningitis is associated with higher cerebrospinal HIV-1 viral loads compared to other HIV-1-associated meningitides. To gain a better understanding of the immunopathogenesis of tuberculous meningitis (TBM) and identify potential diagnostic biomarkers that may discriminate TBM from other HIV-1-associated meningitides, we assessed HIV-1 viral load levels, drug resistance patterns in antiretroviral therapy (ART)-experienced patients with persistent viremia and soluble immunological (...) analytes in peripheral blood and cerebrospinal fluid (CSF) of HIV-1 infected patients with TBM versus other meningitides. One hundred and three matched blood and CSF samples collected from HIV-1 infected patients with TBM or other meningitides presenting at a hospital in Durban, South Africa, from January 2009 to December 2011 were studied. HIV-1 RNA and 28 soluble immunological potential biomarkers were quantified in blood plasma and CSF. Viremic samples were assessed for HIV-1 drug resistance

2018 PLoS ONE

198. Broad HIV epitope specificity and viral inhibition induced by multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults. Full Text available with Trip Pro

Broad HIV epitope specificity and viral inhibition induced by multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults. A correlation between in vivo and in vitro virus control mediated by CD8+ T-cell populations has been demonstrated by CD8 T-cell-mediated inhibition of HIV-1 and SIV replication in vitro in peripheral blood mononuclear cells (PBMCs) from infected humans and non-human primates (NHPs), respectively. Here, the breadth and specificity of T-cell responses (...) induced following vaccination with replication-defective adenovirus serotype 35 (Ad35) vectors containing a fusion protein of Gag, reverse transcriptase (RT), Integrase (Int) and Nef (Ad35-GRIN) and Env (Ad35-ENV), derived from HIV-1 subtype A isolates, was assessed in 25 individuals. The vaccine induced responses to a median of 4 epitopes per vaccinee. We correlated the CD8 responses to conserved vs. variable regions with the ability to inhibit a panel of 7 HIV-1 isolates representing multiple clades

2014 PloS one

199. HLA-B*35: 05 is a protective allele with a unique structure among HIV-1 CRF01_AE-infected Thais, in whom the B*57 frequency is low. Full Text available with Trip Pro

HLA-B*35: 05 is a protective allele with a unique structure among HIV-1 CRF01_AE-infected Thais, in whom the B*57 frequency is low. To identify protective human leukocyte antigen (HLA) alleles in an HIV-infected south-east Asian population, in whom HLA-B*57 prevalence is lower than other ethnic groups, and HIV-1 CRF01_AE is the dominant circulating subtype.Cross-sectional study of Thai patients with chronic HIV infection.Five hundred and fifty-seven HIV-1 CRF01_AE-infected Thais were recruited (...) . Their HLA type and viral load were determined to statistically analyze the association of each allele in viral control. In-silico molecular dynamics was also used to evaluate the effect of HLA structure variants on epitope binding.HLA-B*35:05 was identified as the most protective allele (P=0.003, q=0.17), along with HLA-B*57:01 (P=0.044, q=0.31). Structurally, HLA-B*35:05 belonged to the HLA-B*35-PY group of HLA-B*35 alleles; however, unlike the other HLA-B*35 alleles that carry Arg (R) at residue 97

2014 AIDS

200. A phase 1, open-label safety and immunogenicity study of an AS03-adjuvanted trivalent inactivated influenza vaccine in children aged 6 to 35 months Full Text available with Trip Pro

A phase 1, open-label safety and immunogenicity study of an AS03-adjuvanted trivalent inactivated influenza vaccine in children aged 6 to 35 months  There is a need for better vaccines and vaccine strategies to reduce the burden of influenza in very young children.   This phase 1, open-label study assessed the reactogenicity, safety, and immunogenicity of an inactivated trivalent influenza vaccine (TIV) containing low doses of hemagglutinin antigen (7.5 µg each strain), adjuvanted (...) with a tocopherol-based oil-in-water emulsion Adjuvant System (AS03). Influenza vaccine-naïve children aged 6-35 months were sequentially enrolled to receive TIV-AS03D (1.48 mg tocopherol) or TIV-AS03C (2.97 mg tocopherol), then a 6-month booster of conventional TIV. The primary endpoint was the incidence of fever (axillary temperature >38 °C) for 7 days post-vaccination. Immune responses were assessed by hemagglutination-inhibition (HI) assay. Forty children were sequentially enrolled into the TIV-AS03D

2014 Human vaccines & immunotherapeutics

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>